@B6VECcNetVjoam7 肝臓がんにソラフェニブ（先発名：ネクサバール）とイフェンプロジルの併用筋＠香港 https://t.co/AACWJJ5Jrt

RT @ilyassahinMD: T: CRISPR–Cas9 taraması, #HCC (#karaciğerkanseri ) tedavisi için eyleme geçirilebilir hedefler belirleyerek, klinik olara…

RT @ilyassahinMD: Combinatorial CRISPR–Cas9 screening identifies actionable targets for #HCC therapy, uncovering the potential of combining…

T: CRISPR–Cas9 taraması, #HCC (#karaciğerkanseri ) tedavisi için eyleme geçirilebilir hedefler belirleyerek, klinik olarak onaylanmış ifenprodil ve sorafenib ilaçlarını yeni bir etkili tedavi rejimi olarak birleştirme potansiyelini ortaya çıkarır. https://

Combinatorial CRISPR–Cas9 screening identifies actionable targets for #HCC therapy, uncovering the potential of combining the clinically approved drugs ifenprodil and sorafenib as a new effective treatment regimen. https://t.co/cxN59ztdvV https://t.co/0m0t

A Combinatorial CRISPR-Cas9 Screen Identifies Ifenprodil as an Adȷunct to Sorafenib for Liver Cancer Treatment https://t.co/dy3hxTtBBF https://t.co/diQcCmuN8U

A Combinatorial CRISPR-Cas9 Screen Identifies Ifenprodil as an Adȷunct to Sorafenib for Liver Cancer Treatment https://t.co/8XE3qvh5P3 https://t.co/0aO05Wdaq4

A Combinatorial CRISPR-Cas9 Screen Identifies Ifenprodil as an Adȷunct to Sorafenib for Liver Cancer Treatment https://t.co/sR8u3uGaWi

A combinatorial CRISPR-Cas9 screen identifies ifenprodil as an adjunct to sorafenib for liver cancer treatment: Systematic testing of existing drugs and their combinations is an attractive strategy to exploit approved drugs for repurposing and identify… ht

A combinatorial CRISPR-Cas9 screen identifies ifenprodil as an adjunct to sorafenib for liver cancer treatment https://t.co/ccby3lINn3 https://t.co/3ui3yGF1IM

New article: A combinatorial CRISPR-Cas9 screen identifies ifenprodil as an adjunct to sorafenib for liver cancer treatment https://t.co/QYbnaNNRTd #livercancer #oncology https://t.co/uj7w5dZ4z9